Calidi Biotherapeutics, Inc.
Symbol: CLDI (NYSE)
5.25
▲ (4.09%) 0.206
Company Description:
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
Key Stats
- Today's Open: $5.26
- Today's High: $5.55
- Today's Low: $5.02
- Today's Volume: 80.53K
- Yesterday Close: $5.04
- Yesterday High: $6.0594
- Yesterday Low: $4.85
- Yesterday Volume: 297.21K
- Last Min Volume: 0
- Last Min High: $5.262
- Last Min Low: $5.246
- Last Min VWAP: $0
Company Profile
- Name: Calidi Biotherapeutics, Inc.
- Website: https://www.calidibio.com
- Listed Date: 2023-09-13
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001855485
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $14.50M
- Round Lot: 100
- Outstanding Shares: 2.88M
- Asset Type: CS
RECENT FILINGS FOR CLDI
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-15 | S-1 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | 8-K | View |
| 2025-08-08 | 10-Q | View |
| 2025-08-08 | 8-K | View |
| 2025-08-07 | 8-K | View |
| 2025-07-25 | EFFECT | View |
| 2025-07-25 | 8-K | View |
| 2025-07-18 | S-3 | View |
| 2025-07-15 | 4 | View |
| 2025-07-15 | 4 | View |
| 2025-07-15 | 4 | View |
| 2025-07-15 | 4 | View |
| 2025-07-11 | EFFECT | View |
| 2025-07-11 | 8-K | View |
| 2025-07-10 | CORRESP | View |
| 2025-07-10 | 424B3 | View |
| 2025-07-10 | 424B3 | View |
| 2025-07-10 | 8-K | View |
| 2025-07-08 | UPLOAD | View |
Latest News on CLDI